EUCTR2004-004399-35-GB进行中（未招募）1 期
The effects of eplerenone on left ventricular remodelling post-acute myocardial infarction: a double-blind placebo-controlled cardiac MR-based study.
orth Glasgow Trust0 个研究点目标入组 100 人开始时间: 2005年2月15日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Age 18 or above
- •2. Acute myocardial infarction as defined by standard criteria
- •3. LVSD based on echocardiographic WMSI and LVEF < 40%
- •4. Ability to give written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Clinical or radiological heart failure
- •2. Established diabetes mellitus
- •3. Current use of K-sparing diuretics
- •4. Serum creatinine > 220mmol/l
- •5. Serum potassium > 5.0mmol/l
- •6. Pregnancy
- •7. Addison’s disease
- •8. MRI-incompatible (ferrous) sulphate prosthesis
- •9. Claustrophobia (unable to tolerate MR environment)
研究者
相似试验
已完成
4 期
Effects of Eplerenone on Left Ventricular Remodelling Following Heart AttackMyocardial InfarctionNCT00132093NHS Greater Glasgow and Clyde100
进行中（未招募）
不适用
Evaluation of the effect of a medicine called eplerenone in people with type II diabetes who have evidence of stiffening of the heart muscleEUCTR2011-006123-37-IESolvotrin Innovations Ltd60
已完成
2 期
Comparative study between Spironolactone vs Eplerenonein patients undergoing revascularization with acute myocardial infarction having LV dysfunctioCTRI/2021/10/037504AIIMS BHUBANESWAR88
进行中（未招募）
不适用
The effect of eplerenone versus placebo on cardiovascular mortality and heart failure hospitalization in subjects with NYHA Class II Chronic Systolic Heart Failure - N/AChronic systolic heart failureMedDRA version: 8.0Level: LLTClassification code 10008908EUCTR2005-003351-12-BEPfizer Inc.2,715
进行中（未招募）
不适用
The effect of eplerenone versus placebo on cardiovascular mortality and heart failure hospitalization in subjects with NYHA Class II Chronic Systolic Heart Failure - N/AEUCTR2005-003351-12-PTaboratórios Pfizer, Lda2,584